Fragasso Financial Advisors’s AbbVie ABBV Stock Holding History

Fragasso Financial Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.28M	Buy	21,001 +660	+3%	+$142K	0.28%	39
2026 Q1	$4.2M	Buy	20,341 +248	+1%	+$55K	0.25%	43
2025 Q4	$4.59M	Sell	20,093 -1,065	-5%	-$243K	0.28%	36
2025 Q3	$4.95M	Sell	21,158 -266	-1%	-$54.2K	0.31%	33
2025 Q2	$3.98M	Buy	21,424 +291	+1%	+$54.1K	0.27%	40
2025 Q1	$4.43M	Buy	21,133 +8,361	+65%	+$1.63M	0.33%	36
2024 Q4	$2.27M	Buy	12,772 +180	+1%	+$33.1K	0.17%	72
2024 Q3	$2.49M	Buy	12,592 +409	+3%	+$76.3K	0.19%	73
2024 Q2	$2.09M	Buy	12,183 +229	+2%	+$37.9K	0.17%	75
2024 Q1	$2.18M	Sell	11,954 -27	-0.2%	-$4.65K	0.18%	75
2023 Q4	$1.86M	Sell	11,981 -163	-1%	-$23.8K	0.17%	79
2023 Q3	$1.81M	Buy	12,144 +179	+1%	+$26.3K	0.19%	72
2023 Q2	$1.61M	Buy	11,965 +271	+2%	+$39.7K	0.17%	86
2023 Q1	$1.86M	Buy	11,694 +32	+0.3%	+$4.89K	0.21%	61
2022 Q4	$1.88M	Buy	11,662 +30	+0.3%	+$4.6K	0.22%	63
2022 Q3	$1.56M	Buy	11,632 +56	+0.5%	+$8.04K	0.22%	55
2022 Q2	$1.77M	Sell	11,576 -49	-0.4%	-$7.49K	0.24%	54
2022 Q1	$1.88M	Buy	11,625 +154	+1%	+$22.4K	0.22%	53
2021 Q4	$1.55M	Sell	11,471 -639	-5%	-$75.5K	0.18%	65
2021 Q3	$1.31M	Buy	12,110 +645	+6%	+$73.7K	0.17%	63
2021 Q2	$1.29M	Buy	11,465 +23	+0.2%	+$2.59K	0.17%	64
2021 Q1	$1.24M	Buy	11,442 +103	+0.9%	+$11K	0.17%	67
2020 Q4	$1.22M	Buy	11,339 +62	+0.5%	+$5.96K	0.18%	62
2020 Q3	$988K	Buy	11,277 +69	+0.6%	+$6.5K	0.16%	62
2020 Q2	$1.04M	Buy	11,208 +4,746	+73%	+$418K	0.18%	64
2020 Q1	$492K	Hold	6,462	–	–	0.11%	80
2019 Q4	$572K	Buy	6,462 +135	+2%	+$11.2K	0.1%	91
2019 Q3	$479K	Buy	6,327 +62	+1%	+$4.25K	0.09%	90
2019 Q2	$456K	Buy	6,265 +70	+1%	+$5.5K	0.09%	92
2019 Q1	$499K	Buy	6,195 +70	+1%	+$5.73K	0.11%	79
2018 Q4	$565K	Sell	6,125 -7	-0.1%	-$616	0.13%	91
2018 Q3	$549K	Buy	6,132 +475	+8%	+$45K	0.13%	78
2018 Q2	$524K	Hold	5,657	–	–	0.14%	74
2018 Q1	$535K	Sell	5,657 -74	-1%	-$8.13K	0.13%	74
2017 Q4	$554K	Buy	5,731 +113	+2%	+$10.7K	0.13%	74
2017 Q3	$499K	Buy	+5,618	New	+$428K	0.15%	74
2014 Q4	–	Sell	-5,183	Closed	-$299K	–	46
2014 Q3	$299K	Buy	5,183 +115	+2%	+$6.38K	0.23%	65
2014 Q2	$286K	Sell	5,068 -46	-0.9%	-$2.41K	0.25%	60
2014 Q1	$263K	Hold	5,114	–	–	0.27%	60
2013 Q4	$270K	Buy	+5,114	New	+$251K	0.24%	57

Other funds holding ABBV

LMFP

Larry Mathis Financial Planning Phoenix, Arizona $124B AUM

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

ATO

Alecta Tjanstepension Omsesidigt Stockholm, Sweden $23.8B AUM 34.25% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

HCM

Hamlin Capital Management New York $4.45B AUM 22.95% 1-Year Est. Return

AAMU

AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return

FWCM

Ferguson Wellman Capital Management Portland, Oregon $8.19B AUM 30.56% 1-Year Est. Return

Fragasso Financial Advisors's ABBV Position: Q2 2026 in Review

Fragasso Financial Advisors increased its AbbVie (ABBV) stake by 3.2% in Q2 2026, buying an estimated $142K and bringing the position to 21,001 shares worth $5.28M. The position accounts for 0.28% of the portfolio, ranked #39.

Fragasso Financial Advisors first reported a position in ABBV in Q4 2013 and has held it in 40 quarters since. 1,476 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Fragasso Financial Advisors held 21,001 shares of AbbVie worth $5.28M as of Q2 2026.
Fragasso Financial Advisors bought 660 AbbVie shares in Q2 2026, an estimated $142K.
AbbVie made up 0.28% of Fragasso Financial Advisors's portfolio in Q2 2026, its #39 holding.
Fragasso Financial Advisors first reported a position in AbbVie in Q4 2013 and has held it in 40 quarters since.
1,476 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Fragasso Financial Advisors's 13F filing for Q2 2026, filed 9 Jul 2026.